Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma Clinical research trials and Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma. Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma clinical trial. Human subjects often get the best healthcare possible for their Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.

Home > "G" Clinical Trials Conditions > Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma



Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

For Condition: recurrent neuroblastoma
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , St. Jude Children's Research Hospital
Synopsis: RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.
Details: OBJECTIVES: I. Determine the safety in children of recurrent neuroblastoma of two weekly subcutaneous injections of autologous, or partially HLA-matched allogeneic, neuroblastoma cells that have been modified by insertion of the interleukin-2 gene introduced by a retroviral vector. II. Determine whether multiple histocompatibility-restricted or unrestricted antitumor immune responses are induced by this treatment and the cell dose required to produce these effects. III. Obtain preliminary data on the antitumor effects of this regimen. PROTOCOL OUTLINE: Autologous or partially HLA-matched allogeneic neuroblastoma cells are transduced with a human gene for interleukin-2 production. Patients receive subcutaneous injections of the gene-modified cells on days 1 and 8, with the second injection containing 10 times more cells than the first injection. After a 3-4 week rest, stable and responding patients may receive additional weekly injections at the second dose. Cohorts of 3-6 patients will be entered at increasing cell doses until the maximum tolerated dose is estimated. Multiple injection sites may be used at the higher cell-dose levels. Patients are followed every week for 6 weeks, every other week for 6 weeks, and monthly for 1 year. Additional visits may be required as clinically indicated. PROJECTED ACCRUAL: Approximately 12 patients each will be entered into the autologous and the partially HLA-matched allogeneic tumor cell treatment groups. Accrual is expected to require 4 years for the autologous tumor cell group and 2 years for the partially HLA-matched allogenic tumor cell group.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: /21 Years
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven high risk neuroblastoma at the completion of planned primary therapy; No rapidly progressing disease - Allogeneic transduced cell line available; Demonstrated production of at least 150 picograms of interleukin-2 per 10 to the 6th cells per day --Prior/Concurrent Therapy-- - See Disease Characteristics; Recovered from prior chemotherapy; No concurrent antibiotics except prophylactic trimethoprim/sulfamethoxazole; No concurrent drugs other than analgesics --Patient Characteristics-- - Age: Under 21 at diagnosis - Performance status: ECOG 0-2 - Life expectancy: At least 8 weeks - Hematopoietic: (unless marrow replaced by tumor); Absolute neutrophil count greater than 500/mm3; Platelet count greater than 50,000/mm3 - Hepatic: Bilirubin less than 1.5 mg/dL; AST no greater than 2 times normal; PT normal - Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance greater than 80 mL/min; Urinalysis normal - Metabolic: Electrolytes (including calcium, phosphate) normal; Glucose normal; Weight greater than 10th percentile for age; Albumin greater than 3 g/dL - Other: No active infection; HIV negative; Not pregnant or nursing
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
GregoryHale,  Study Chair,  St. Jude Children's Research Hospital

Saint Jude Children's Research Hospital
Memphis,  Tennessee,  38105-2794
United States
 


Additional Information:
Study ID Numbers:  CDR0000064681;  SJCRH-CYGENE,NCI-H96-0005,SJCRH-CYGNE2
Study Start Date: August 2000
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002748

Other Recurrent Neuroblastoma Studies:
1. Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

2. Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation in Treating Patients With Refractory Neuroblastoma

3. Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

4. Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

5. Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Related Studies:

Other recurrent neuroblastoma Clinical Trials
Other Tennessee Clinical Trials
Other Memphis Clinical Trials

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
Modify your Search

  Other recurrent neuroblastoma Clinical Trials
  Other Tennessee Clinical Trials
  Other Memphis Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103